Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dreno, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dreno, B.

Stem Cells, Vol 11, 269-275, Copyright © 1993 by AlphaMed Press

REVIEWS

Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas

B Dreno
Department of Dermatology, C.H.U., Nantes, France.

Many treatments are used for epidermotropic cutaneous T cell lymphomas (CTCL) such as mycosis fungoides (MF) and Sezary syndrome (SS). All pretend to be effective, but none is really curative. As single drug therapy provides a response rate of about 55% with interferon alpha and about 45% with etretinate, we studied the effectiveness of combining these two drugs for immunomodulatory therapy in epidermotropic CTCL. A review of four reports, including a multicenter study performed in 45 patients, indicates a response rate of 56%, with better results for MF than SS. Side effects are generally moderate when low doses are used. The mechanism of action of this combined therapy on cutaneous lesions remains unclear. In vitro, a synergistic effect of retinoids on interferon alpha antiviral activity has been demonstrated, and in vivo an immunohistochemical study showed that the combined therapy modulates antigens expressed by keratinocytes and increases cytotoxic cells in dermis without modifying the number of Langerhans cells in epidermis.


This article has been cited by other articles:


Home page
 J. Am. Coll. Nutr.Home page
K. N. Prasad, W. C. Cole, B. Kumar, and K. C. Prasad
Scientific Rationale for Using High-Dose Multiple Micronutrients as an Adjunct to Standard and Experimental Cancer Therapies
J. Am. Coll. Nutr., October 1, 2001; 20(90005): 450S - 463.
[Abstract] [Full Text]

Home page
 JCOHome page
R. S. Siegel, T. Pandolfino, J. Guitart, S. Rosen, and T. M. Kuzel
Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts
J. Clin. Oncol., August 15, 2000; 18(15): 2908 - 2925.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
K. N. Prasad, A. Kumar, V. Kochupillai, and W. C. Cole
High Doses of Multiple Antioxidant Vitamins: Essential Ingredients in Improving the Efficacy of Standard Cancer Therapy
J. Am. Coll. Nutr., February 1, 1999; 18(1): 13 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
T. C. Roos, F. K. Jugert, H. F. Merk, and D. R. Bickers
Retinoid Metabolism in the Skin
Pharmacol. Rev., June 1, 1998; 50(2): 315 - 333.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 1993 by AlphaMed Press.